Niveaux de preuve insuffisants

La TEP-FDG est discutée :

- à visée pronostique en cas de métastases d’emblée (révélatrices du cancer ou diagnostiquées au moment de l’ablation) fixant ou non l’iode 131.

- lorsqu’il existe au cours de la surveillance une élévation confirmée du taux de thyroglobuline quelle que soit les résultats de la scintigraphie après dose traceuse ou thérapeutique d’iode 131.

113

114

[1]. Olivier CHABRE. Cancers de la thyroïde Avril 2003 Corpus Médical–

Faculté de Médecine de Grenoble. http://www-sante.ujf-grenoble.fr/SANTE/ 1/8

[2]. Kursat Okuyucu, Engin Alagoz, Nuri Arslan, Ozdes Emer, Semra Ince,

Salih Deveci, Asli Ayan, Abdullah Taslipinar, Bengul Gunalp ad Omar Azal. Clinicopathologic features and prognostic factors of tall cell variant of papillary thyroide carcinoma: comparison with classic variant of papillary thyroid carcinoma.Nuclear medicine communications 2015; 36:1021-1025

[3]. N. Berger, A. Borda, M. Decaussin-Petrucci. Médecine Nucléaire -

Imagerie fonctionnelle et métabolique 2003 ; vol.27 - n°3 : p127-30

[4]. LAHLAIDI A. Anatomie topographique du cou : p 192-7

[5]. Institut National pour la Santé Et la Recherche Médicale INSERM Cancer

et environnement 2008 ; chap 10-12 : p 647-871

[6]. Schlumberger M. Cancer papillaire et folliculaire de la thyroïde.

Encyclopédie Orphanet. Juin 2007

[7]. Benrais Aouad N, Ghfir I, Missoum F. Aspects épidémiologiques du

cancer différencié de la thyroïde (médullaire exclu) au Maroc. Médecine nucléaire 2008 ; 32 ; 580-584.

[8]. Zorkani Y. La radioprotection lors de l’irathérapie forte dose cas du

cancer différencié de la thyroïde. Thèse de médecine (Rabat) 2010 ; 245 ; p17-20

[9]. Perlemuler L, Thomas J-L. endocrinologie connaissances et pratiques 5^ème

115

[10]. L. Leenhardt, F. Ménégaux, B. Franc, C. Hoang, S. Salem, M.-O. Bernier, L. Dupasquier-Fédiaevsky, E. Le Marois, A. Rouxel, J.-P. Chigot, L. Chérié-Challine, A. Aurengo. Cancers de la thyroïde ; EMC - Endocrinologie Fevrier 2005: Volume 2, Issue 1, Pages 1–38

[11]. Aubène L. Pathologie thyroïdienne diagnostic et traitement ; 4^ème édition (médecine science Flammarion) : ISBN 2-257-13205-X : 2001 : p172-4

[12]. Hong-Jun Song, Yan-Li Xue, Yan-Hong Xu, Zhong-Ling Qiu1 and

Quan-Yong Luo. Rare metastases of differentiated thyroid carcinoma: pictorial review: Endocrine-Related Cancer 2011; 18 R165–R174

[13]. Annales d’Endocrinologie (Annals of Endocrinology). Recommandations

pour la prise en charge des cancers thyroïdiens différenciés. Novembre 2007 ; Vol 68-suppl.2-pS53-S94

[14]. L. LEENHARDT, F. MENEGAUX, B. FRANC, C. HOANG, S. SALEM,

M.O. BERNIER, L. DUPASQUIER-FEDIAVESKY, E. LE MAROIS, A. ROUXEL, J.P. CHIGOT, L. CHERIE-CHALLINE, A. AURENGO. Cancers de la thyroïde. Encyclopédie médico-chirurgicale 2015. 10-008-A-50.

[15]. Raja Sfar, Tarek Kamoun, Manel Nouira, Hamza Regaieg, Nouha

Ammar, Hela Charfi, Achraf Bahloul, Maha Ben Fredj, Kaouther Chatti, Mohsen Guezguez, Habib Essabbah. Differentiated Thyroid Cancer with Thyroglobulin Elevation and Negative Iodine Scintigraphy (TENIS Syndrome). International Journal of Otolaryngology and Head & Neck Surgery, 2014; 3- 149-153

[16]. Domenico Rubello, Patrick Colletti and Gary J. Cook. What is the role of

radionuclide sentinel lymph node biopsy and dissection in papillary thyroid cancer? Nuclear medicine communications 2015; 36:969-970

116

[17]. Chao Ma. Differentiated Thyroid Carcinoma with Elevated Thyroglobulin and Negative Radioiodine Whole-Body Scan Metastases. In Thyroid Cancer - Advances in Diagnosis and Therapy 2016; p148-170 (Book) http://dx.doi.org/10.5772/64356

[18]. Kayods S. Data on repeated 131I-WB scans and the incidence of positive

Tg and negative 131I-WBS in DTC patients from a 24-month study. Hell J Nucl Med 2011; 14(2)

[19]. Caetano R, Bastos CR, de Oliveira IA, da Silva RM, Fortes CP, Pepe VL,

Reis LG and Braga JU. Accuracy of positron emission tomography and positron emission tomography-CT in the detection of differentiated thyroid cancer recurrence with negative (131) I whole-body scan results: A meta-analysis. Head and Neck 2016; 38:316–327.

[20]. June-key Chung, Young So, Jae Sung Lee, Chang Woon Choi, Sang Moo

Lin, Dong Soo Lee, Sung Woon Hong, Yeo Kyu Youn, Myung Chul Lee and Boyoun Cho. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. J Nucl Med 1999 ; 40 :986-992

[21]. F. Giammarile, F. Borson-Chazot. Intérêt comparé de la scintigraphie au

18FDG et de la scintigraphie à l’Octréoscan pour localiser les récidives des cancers thyroïdiens différenciés ne fixant pas l’iode 131. Médecine Nucléaire - Imagerie fonctionnelle et métabolique 2003 ; vol.27 : n°4

[22]. Yuka Yamamoto, MD; Yoshihiro Nishiyama, MD; Toshihide Monden;

Yoshitaka Matsumura; Katashi Satoh, MD;and Motoomi Ohkawa, MD. Clinical Usefulness of Fusion of 131I SPECT and CT Images in Patients with Differentiated Thyroid. JOURNAL OF NUCLEAR MEDICINE December 2003; Vol. 44: No. 12

117

[23]. Y.A. Onimode, A.B. Rahmani , M.D.T. Vangu. An unusual presentation

of the TENIS syndrome. Egyptian Journal of Ear, Nose, Throat and Allied Sciences 2013; 14, 37–40

[24]. Massimo Salvatori, Bernadette Biondi, Vittoria Rufini.

[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in differentiated thyroid carcinoma: clinical indications and controversies in diagnosis and follow-up. European Journal of Endocrinology 2015; 173, R115–R130

[25]. Elif Ozdemir, Nilufer Yildirim Poyraz, Sefika Burcak Polat, Seyda

Turkolmez, Reyhan Ersoy, Bekir Cakir. Diagnostic value of 18F-FDG PET/CT in patients with TENIS syndrome: correlation with thyroglobulin levels. Ann Nucl Med 2014; 28:241–247

[26]. Beate Schlüter, Karl H. Bohuslavizki, Wolfgang Beyer, Mykaylo Plotkin,

Ralph Buchert, and Malte Clausen. Impact of FDG PET on Patients with Differentiated Thyroid Cancer Who Present with Elevated Thyroglobulin and Negative 131I Scan. J Nucl Med 2001; 42:71–76

[27]. Chao Ma, Jiawei Xie1, Yanhui Lou1, Yanyan Gao2, Shuyao Zuo, Xufu

Wang. The role of TSH for 18F-FDG-PET in the diagnosis of recurrence and metastases of differentiated thyroid carcinoma with elevated thyroglobulin and negative scan: a meta-analysis. European Journal of Endocrinology 2010; 163 177–183

[28]. Rohit Ranade, Purushottam Kand and Sandip Basu. Value of 18F-FDG

PET negativity and Tg suppressibility as markers of prognosis in patients with elevated Tg and 131I-negative differentiated thyroid carcinoma (TENIS syndrome). Nuclear medicine communication 2015; 36:1014-1020

118

[29]. Leboulleux S, Schroeder PR, Busaidy NL, Auperin A, Corone C, Jacene

HA, Ewertz ME, Bournaud C, Wahl RL, Sherman SI, Ladenson PW and Schlumberger M. Assessment of the incremental value of recombinant thyrotropin stimulation before [18F]- Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. The Journal of Clinical Endocrinology and Metabolism. 2009; 94:1310–1316.

[30]. Sandip Basul, Mitali Dandekar, Amit Joshi, Anil D’Cruz. Defining a

rational step-care algorithm for managing thyroid carcinoma patients with elevated thyroglobulin and negative on radioiodine scintigraphy (TENIS): considerations and challenges towards developing an appropriate roadmap. Eur J Nucl Med 2015; 42:1167–1171

[31]. Torjan Haslerud, Katrin Brauckhoff, Lars Reisæter, Regina Küfner-Lein,

Achim Heinecke, Jan Erik Varhaug, Martin Biermann. F18-FDG-PET for recurrent differentiated thyroid cancer: a systematic meta-analysis. The Foundation Acta Radiologica 2015; 10.1177/0284185115594645

[32]. Dong M-J, Liu Z-F, Zhao K, et al. Value of 18F-FDG-PET/PET-CT in

differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis. Nucl Med Commun 2009; 30:639–650.

[33]. ELBOGA, U., KARAOGLAN, H., SAHIN, E., et al. F-18 FDG PET/CT

imaging in the diagnostic work-up of thyroid cancer patients with high serum thyroglobulin, negative I-131 whole body scan and suppressed thyrotropin: 8-year experience. European review for medical and pharmacological sciences 2015; 19: 396-401.